Latest News
Global Markets Update: SEBI Bars JPMorgan Arm, WSP Pursues Arcadis, and More
India's SEBI bars JPMorgan entity over auction manipulation; WSP presses Arcadis bid; German PPI accelerates; Skanska wins data center deal; IDP plunges; China holds rates.
easyJet Axes Leeds Operations Amid Apollo Takeover Pressure
easyJet is exiting Leeds Bradford Airport entirely, dropping six routes by January 2027. The move, representing less than 0.6% of its network, underscores capacity discipline as Apollo's £7.15/share takeover offer progresses.
DraftKings Rises 5% as MLB Promo Costs Cloud Margin Outlook
DraftKings stock climbed 5.3% as MLB promotions boosted interest, but Q2 results reveal declining revenue per user and compressed margins. Analysts see upside despite lowered targets.
Gold Miners Outperform Bullion as Prices Near $4,500
Gold nears $4,500 as mining stocks rally over 9%, doubling bullion gains. ETF inflows and falling yields support the precious metal.
CBA Shares Slide 8.8% Despite Record Profit as Valuation Premium Persists
Commonwealth Bank shares tumbled 8.8% over the past week even after posting a record annual profit, as its rich valuation and rising credit concerns weigh on investor sentiment.
AgBank Leads Big Four with 4.5% Profit Gain, But Margin Squeeze Lingers
Agricultural Bank of China outpaced its Big Four peers with 4.52% first-quarter profit growth, though its net interest margin slipped to 1.26%. Shares rose 2.58%.
CSL Surges Past Analyst Targets After Robust Two-Day Rally
CSL shares soared 23.7% in two sessions, surpassing pre-results analyst targets. The biotech's underlying profit stability and A$1.1 billion buyback fueled investor optimism.
SpaceX Shares Slide 2.6% as 319 Million-Share Lockup Expiry Looms
SpaceX shares dropped 2.6% to $139.65 as a 319 million-share lockup expiry approaches, representing 4.4 times Wednesday's volume. The stock remains 3.4% above its IPO price.
HSBC's Modest Buyback Signals Caution Amid Thin Capital Buffer
HSBC's $1B buyback is more signal than support, as its CET1 ratio sits near the lower end of its target range, prompting caution despite strong earnings.
Roche Jumps on $9B Breast Cancer Drug Forecast
Roche shares gained 1.5% after Morgan Stanley forecast CHF9B peak sales for its breast cancer drug giredestrant, a bullish signal for the pharma giant.
Arm's Analyst Upside Narrows to 4% as Valuation Remains Steep
Arm's stock fell 1.6% to $249.34, leaving only 4.3% upside to the median analyst target. The average target is skewed by a $500 high estimate, while valuation remains far above peers.